Effects of Exenatide on Hypothalamic Obesity

Completed · Phase 1/Phase 2

Conditions studied: Hypothalamic Obesity

In brief

The primary aim of this study is to evaluate the effect of Exenatide on weight status (change in body mass index) of children treated for craniopharyngioma that have developed hypothalamic obesity at Children's Hospitals and Clinics of Minnesota. We hypothesize that Exenatide given to hypothalamic obese children for 6 months will reduce their body mass index significantly from baseline.

Key facts

Study ID

NCT01061775

Run by

Children's Hospitals and Clinics of Minnesota

People needed

19

Starts

2010-01-01

Expected to finish

2019-03-15

Last updated by the study team

2019-10-08

Who can join

Age: 10 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• >/=6 months post surgical or radiation or chemotherapy treatment for 1° craniopharyngiomas or other suprasellar tumors
• 10-21 years old
• Age-and sex-adjusted BMI >/=95%
• Parent sign consent and patient sign assent

You may not qualify if…

• < 6 months post surgical or radiation or chemotherapy treatment for 1° craniopharyngiomas or other suprasellar tumors
• Pregnant or breastfeeding, or those women who plan to get pregnant
• Renal impairment
• Gastroparesis
• Pancreatitis
• Diabetes
• <1 month post initiation of Metformin treatment
• Prescription or over-the-counter weight loss medications within 3 months of screening
• Are actively participating in, or have participated in a formal weight loss program within the last 3 months
• Have had bariatric surgery

Where it is running

• Children's Hospital of Orange County — Orange, California, United States
• Children's Hospitals & Clincis of Minnesota — Saint Paul, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.